Correction to: Nature Aging https://doi.org/10.1038/s43587-021-00138-z. Published online 6 December 2021.

In the version of this article initially published, we used the term “active comparator design” to describe our study design. Since a true active comparator design would require using a drug with an indication for which the drug has predominantly been used (at least in the databases we utilized), this was an inaccurate description of our study design. Thus we are correcting the description by removing the phrase “using a new-user active comparator design21” from the end of the text now reading “To minimize confounding factors, we conducted three types of drug cohort-based observational studies: (1) sildenafil users versus non-sildenafil users; (2) sildenafil versus a comparator drug (diltiazem or glimepiride) without reported preclinical and clinical evidence of AD relevance; and (3) sildenafil versus a comparator drug (losartan or metformin) in active AD clinical trials.” This change does not impact any conclusion of the original article. The change is reflected in the HTML and PDF versions of the article.